Search research articles
Contact Us
Filters
Showing results (151-160 of 244) with videos related to
Page
of 25
Sort By:
Blood Reviews
|
September 1, 1994
The role of fludarabine in hematological malignancies
S J Wright, L E Robertson, S O'Brien, et al.
Cancer Research
|
February 28, 2001
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
Z Shi, A Azuma, D Sampath, et al.
Leukemia
|
August 15, 2000
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
P Huang, A Sandoval, E Van Den Neste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia
V Gandhi, E Estey, M Du, et al.
Leukemia
|
November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemia
M J Keating, S O'Brien, L Robertson, et al.
Cancer Research
|
November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia
R Grunewald, H Kantarjian, M J Keating, et al.
Leukemia
|
August 1, 1987
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
E Estey, W Plunkett, D Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia
V Gandhi, W Plunkett, H Kantarjian, et al.
Leukemia
|
March 1, 1996
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome
L E Robertson, W Plunkett, K McConnell, et al.
Leukemia & Lymphoma
|
January 1, 1993
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C
E H Estey, W Plunkett, H Kantarjian, et al.
Page
of 25
Search research articles
Search
Showing results (151-160 of 244) with videos related to
Sort By:
Page
of 25
Blood Reviews
|
September 1, 1994
The role of fludarabine in hematological malignancies
S J Wright, L E Robertson, S O'Brien, et al.
Cancer Research
|
February 28, 2001
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
Z Shi, A Azuma, D Sampath, et al.
Leukemia
|
August 15, 2000
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
P Huang, A Sandoval, E Van Den Neste, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia
V Gandhi, E Estey, M Du, et al.
Leukemia
|
November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemia
M J Keating, S O'Brien, L Robertson, et al.
Cancer Research
|
November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia
R Grunewald, H Kantarjian, M J Keating, et al.
Leukemia
|
August 1, 1987
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
E Estey, W Plunkett, D Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia
V Gandhi, W Plunkett, H Kantarjian, et al.
Leukemia
|
March 1, 1996
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome
L E Robertson, W Plunkett, K McConnell, et al.
Leukemia & Lymphoma
|
January 1, 1993
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C
E H Estey, W Plunkett, H Kantarjian, et al.
Page
of 25